Diagnosis, progression patterns and prognostication in mastocytosis

Expert Review of Hematology

Volumn 5, Issue 3, 2012, Pages 261-274

  Sperr, Wolfgang R ^a   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

diagnosis; mastocytosis; prognosis; progression; therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ALKALINE PHOSPHATASE; ANTIHISTAMINIC AGENT; BETA 2 MICROGLOBULIN; CD2 ANTIGEN; CD36 ANTIGEN; CROMOGLYCATE DISODIUM; GLUCOCORTICOID; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 3; INTERLEUKIN 4 RECEPTOR; KETOTIFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PSORALEN; STEM CELL FACTOR; TRYPTASE;

ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIGEN EXPRESSION; BONE MARROW BIOPSY; BONE PAIN; CELL DIFFERENTIATION; CELL MATURATION; COLONY FORMATION; DARIER DISEASE; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FLUSHING; GENETIC POLYMORPHISM; HEADACHE; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HYPOTENSION; MACULOPAPULAR RASH; MALABSORPTION; MAST CELL; MASTOCYTOSIS; OSTEOLYSIS; PATHOGENESIS; POINT MUTATION; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; PRURITUS; PUVA; REVIEW; SHOCK; SPLENOMEGALY; URTICARIA PIGMENTOSA;

DISEASE PROGRESSION; HUMANS; MAST CELLS; MASTOCYTOSIS; MUTATION; PROGNOSIS; STEM CELL FACTOR;

EID: 84863804826     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.12     Document Type: Review

References (128)

1. Valent P, Horny H-P, Li CY et al. Mastocytosis (MC disease). In: World Health Organization (WHO) Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds). IARC Press, Lyon, France, 291-302 (2001).
2. Swerdlow SH, Campo E, Harris NL et al. Mastocytosis (MC disease). In: World Health Organization (WHO) Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Horny HP, Akin C, Metcalfe DD et al. (Eds). IARC Press, Lyon, France, 54-63 (2008).
3. Akin C, Metcalfe DD. Systemic mastocytosis. Annu. Rev. Med. 55, 419-432 (2004).
4. Valent P, Akin C, Sperr WR et al. Mastocytosis: Pathology, genetics, and current options for therapy. Leuk. Lymphoma 46(1), 35-48 (2005).
5. Metcalfe DD. MCs and mastocytosis. Blood 112(4), 946-956 (2008).
6. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: State of the art in 2010 and future perspectives. Expert Rev. Hematol. 3(4), 497-516 (2010).
7. Valent P, Sperr WR, Akin C. How I treat patients with advanced systemic mastocytosis. Blood 116(26), 5812-5817 (2010).
8. Valent P, Akin C, Arock M et al. Definitions, criteria and global classification of MC disorders with special reference to MC activation syndromes: A consensus proposal. Int. Arch. Allergy Immunol. 157(3), 215-225 (2012).
9. Akin C, Valent P, Metcalfe DD. MC activation syndrome: Proposed diagnostic criteria. J. Allergy Clin. Immunol. 126(6), 1099.e4-1104.e4 (2010).
10. Molderings GJ, Brettner S, Homann J, Afrin LB. MC activation disease: A concise practical guide for diagnostic workup and therapeutic options. J. Hematol. Oncol. 4, 10 (2011).
11. Homann J, Kolck UW, Ehnes A, Frieling T, Raithel M, Molderings GJ. Systemic mastocytosis definition of an internal disease. Med. Klin. 105(8), 544-553 (2010).
12. Koga H, Kokubo T, Akaishi M, Iida K, Korematsu, S. Neonatal onset diffuse CM: A case report and review of the literature. Pediatr. Dermatol. 28(5), 542-546 (2011).
13. Valent P, Horny HP, Escribano L et al. Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk. Res. 25(7), 603-625 (2001).
14. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L et al. Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J. Allergy Clin. Immunol. 124(3), 514-521 (2009).
15. Lim KH, Tefferi A, Lasho TL et al. Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood 113(23), 5727-5736 (2009).
16. Escribano L, Orfao A, Díaz-Agustin B et al. Indolent systemic MC disease in adults: Immunophenotypic characterization of bone marrow MCs and its diagnostic implications. Blood 91(8), 2731-2736 (1998).
17. Sperr WR, Escribano L, Jordan JH et al. Morphologic properties of neoplastic MCs: Delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk. Res. 25(7), 529-536 (2001).
18. Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N. Engl. J. Med. 344(4), 307-309 (2001).
19. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ et al. Cladribine therapy for systemic mastocytosis. Blood 102(13), 4270-4276 (2003).
20. Friedman B, Darling G, Norton J, Hamby L, Metcalfe D. Splenectomy in the management of systemic MC disease. Surgery 107(1), 94-100 (1990).
21. Böhm A, Sonneck K, Gleixner KV et al. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic MCs exhibiting the imatinib-resistant KIT mutation D816V. Exp. Hematol. 38(9), 744-755 (2010).
22. Hauswirth AW, Simonitsch-Klupp I, Uffmann M et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature. Leuk. Res. 28(3), 249-257 (2004).
23. Castells M. MC mediators in allergic inflammation and mastocytosis. Immunol. Allergy Clin. North Am. 26(3), 465-485 (2006).
24. Escribano L, Akin C, Castells M, Schwartz LB. Current options in the treatment of MC mediator-related symptoms in mastocytosis. Inflamm. Allergy Drug Targets 5(1), 61-77 (2006).
25. Wolff K. Treatment of CM. Int. Arch. Allergy Immunol. 127(2), 156-159 (2002).
26. Austen KF. Systemic mastocytosis. N. Engl. J. Med. 326(9), 639-640 (1992).
27. Metcalfe DD. The treatment of mastocytosis: An overview. J. Invest. Dermatol. 96(Suppl. 3), 55S-56S; discussion 56S (1991).
28. Nagata H, Worobec AS, Oh CK et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl Acad. Sci. USA 92(23), 10560-10564 (1995).
29. Longley BJ, Tyrrell L, Lu SZ et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human MC neoplasm. Nat. Genet. 12(3), 312-314 (1996).
30. Fritsche-Polanz R, Jordan JH, Feix A et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br. J. Haematol. 113(2), 357-364 (2001).
31. Féger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: A short overview with special reference to novel molecular and diagnostic concepts. Int. Arch. Allergy Immunol. 127(2), 110-114 (2002).
32. Garcia-Montero AC, Jara-Acevedo M, Teodosio C et al. KIT mutation in MCs and other bone marrow hematopoietic cell lineages in systemic MC disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108(7), 2366-2372 (2006).
33. Furitsu T, Tsujimura T, Tono T et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human MC leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92(4), 1736-1744 (1993).
34. Piao X, Bernstein A. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of MCs. Blood 87(8), 3117-3123 (1996).
35. Mayerhofer M, Gleixner KV, Hoelbl A et al. Unique effects of KIT D816V in BaF3 cells: Induction of cluster formation, histamine synthesis, and early MC differentiation antigens. J. Immunol. 180(8), 5466-5476 (2008).
36. Horny HP, Valent P. Diagnosis of mastocytosis: General histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk. Res. 25(7), 543-551 (2001).
37. Schernthaner GH, Jordan JH, Ghannadan M et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic MCs. Blood 98(13), 3784-3792 (2001).
38. Pardanani A, Tefferi A. Systemic mastocytosis in adults: A review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr. Opin. Hematol. 17(2), 125-132 (2010).
39. Valent P, Akin C, Sperr WR et al. Aggressive systemic mastocytosis and related MC disorders: Current treatment options and proposed response criteria. Leuk. Res. 27(7), 635-641 (2003).
40. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103(8), 3222-3225 (2004).
41. Gotlib J. KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol. Allergy Clin. North Am. 26(3), 575-592 (2006).
42. Gotlib J, Berubé C, Growney JD et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with MC leukemia with the D816V KIT mutation. Blood 106(8), 2865-2870 (2005).
43. Bodemer C, Hermine O, Palmérini F et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J. Invest. Dermatol. 130(3), 804-815 (2010).
44. Pignon JM, Giraudier S, Duquesnoy P et al. A new c-kit mutation in a case of aggressive MC disease. Br. J. Haematol. 96(2), 374-376 (1997).
45. Longley BJ Jr, Metcalfe DD, Tharp M et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl Acad. Sci. USA 96(4), 1609-1614 (1999).
46. Pullarkat VA, Bueso-Ramos C, Lai R et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: Analysis of clinicopathologic features and activating c-kit mutations. Am. J. Hematol. 73(1), 12-17 (2003).
47. Sotlar K, Escribano L, Landt O et al. Onestep detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am. J. Pathol. 162(3), 737-746 (2003).
48. Nakagomi N, Hirota S. Juxtamembranetype c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab. Invest. 87(4), 365-371 (2007).
49. Büttner C, Henz BM, Welker P, Sepp NT, Grabbe J. Identification of activating c-kit mutations in adult-, but not in childhoodonset indolent mastocytosis: A possible explanation for divergent clinical behavior. J. Invest. Dermatol. 111(6), 1227-1231 (1998).
50. 34+ cells. Leuk. Lymphoma 49(8), 1567-1577 (2008).
51. Hartmann K, Wardelmann E, Ma Y et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 129(3), 1042-1046 (2005).
52. Hoffmann KM, Moser A, Lohse P et al. Successful treatment of progressive CM with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood 112(5), 1655-1657 (2008).
53. Mital A, Piskorz A, Lewandowski K, Wasag B, Limon J, Hellmann A. A case of MC leukaemia with exon 9 KIT mutation and good response to imatinib. Eur. J. Haematol. 86(6), 531-535 (2011).
54. Tang X, Boxer M, Drummond A, Ogston P, Hodgins M, Burden AD. A germline mutation in KIT in familial diffuse CM. J. Med. Genet. 41(6), e88 (2004).
55. Zhang LY, Smith ML, Schultheis B et al. A novel K509I mutation of KIT identified in familial mastocytosis - In vitro and in vivo responsiveness to imatinib therapy. Leuk. Res. 30(4), 373-378 (2006).
56. Wasag B, Niedoszytko M, Piskorz A et al. Novel, activating KIT-N822I mutation in familial CM. Exp. Hematol. 39(8), 859.e2-865.e2 (2011).
57. Escribano L, Orfao A, Villarrubia J et al. Sequential immunophenotypic analysis of MCs in a case of systemic MC disease evolving to a MC leukemia. Cytometry 30(2), 98-102 (1997).
58. Teodosio C, García-Montero AC, Jara-Acevedo M et al. MCs from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J. Allergy Clin. Immunol. 125(3), 719-726, 726.e1 (2010).
59. Nedoszytko B, Niedoszytko M, Lange M et al. IL-13 promoter gene polymorphism -1112C/T is associated with the systemic form of mastocytosis. Allergy 64(2), 287-294 (2009).
60. Daley T, Metcalfe DD, Akin C. Association of the Q576R polymorphism in the IL-4 receptor alpha chain with indolent mastocytosis limited to the skin. Blood 98(3), 880-882 (2001).
61. Valent P, Akin C, Escribano L et al. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria. Eur. J. Clin. Invest. 37(6), 435-453 (2007).
62. Escribano L, Díaz-Agustín B, Bellas C et al. Utility of flow cytometric analysis of MCs in the diagnosis and classification of adult mastocytosis. Leuk. Res. 25(7), 563-570 (2001).
63. Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy. Leuk. Res. 25(7), 571-576 (2001).
64. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N. Engl. J. Med. 316(26), 1622-1626 (1987).
65. Sperr WR, Jordan JH, Fiegl M et al. Serum tryptase levels in patients with mastocytosis: Correlation with MC burden and implication for defining the category of disease. Int. Arch. Allergy Immunol. 128(2), 136-141 (2002).
66. Horny HP, Sotlar K, Valent P. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: A review. Pathobiology 77(4), 169-180 (2010).
67. Sotlar K, Horny HP, Simonitsch I et al. CD25 indicates the neoplastic phenotype of MCs: A novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am. J. Surg. Pathol. 28(10), 1319-1325 (2004).
68. Jordan JH, Schernthaner GH, Fritsche-Polanz R et al. Stem cell factorinduced bone marrow MC hyperplasia mimicking systemic mastocytosis (SM): Histopathologic and morphologic evaluation with special reference to recently established SM-criteria. Leuk. Lymphoma 43(3), 575-582 (2002).
69. Sperr WR, El-Samahi A, Kundi M et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: A novel diagnostic approach and screen marker in clinical haematology. Eur. J. Clin. Invest. 39(10), 914-923 (2009).
70. Sperr WR, Stehberger B, Wimazal F et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk. Lymphoma 43(5), 1097-1105 (2002).
71. Sotlar K, Cerny-Reiterer S, Petat-Dutter K et al. Aberrant expression of CD30 in neoplastic MCs in high-grade mastocytosis. Mod. Pathol. 24(4), 585-595 (2011).
72. Valent P, Cerny-Reiterer S, Herrmann H et al. Phenotypic heterogeneity and target expression profiles of normal and neoplastic MCs. Best. Pract. Res. Clin. Haematol. 23(3), 369-378 (2010).
73. Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Smouldering mastocytosis: A novel subtype of systemic mastocytosis with slow progression. Int. Arch. Allergy Immunol. 127(2), 137-139 (2002).
74. Sotlar K, Marafioti T, Griesser H et al. Detection of c-kit mutation Asp 816 to Val in microdissected bm infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol. Pathol. 53(4), 188-193 (2000).
75. Sotlar K, Colak S, Bache A et al. Variable presence of KITD816V in clonal haematological on-MC lineage diseases associated with systemic mastocytosis (SM-AHNMD). J. Pathol. 220(5), 586-595 (2010).
76. Jordan JH, Fritsche-Polanz R, Sperr WR et al. A case of 'smouldering' mastocytosis with high MC burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. Leuk. Res. 25(7), 627-634 (2001).
77. Butterfield JH. Systemic mastocytosis: Clinical manifestations and differential diagnosis. Immunol. Allergy Clin. North Am. 26(3), 487-513 (2006).
78. Sonneck K, Florian S, Müllauer L et al. Diagnostic and subdiagnostic accumulation of MCs in the bone marrow of patients with anaphylaxis: Monoclonal MC activation syndrome. Int. Arch. Allergy Immunol. 142(2), 158-164 (2007).
79. González-De-Olano D, Alvarez-Twose I, Matito A, Sánchez-Muñoz L, Kounis NG, Escribano L. MC activation disorders presenting with cerebral vasospasm-related symptoms: A "Kounis-like" syndrome? Int. J. Cardiol. 150(2), 210-211 (2011).
80. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of CM. Leuk. Res. 25(7), 519-528 (2001).
81. Hartmann K, Bruns SB, Henz BM. Mastocytosis: Review of clinical and experimental aspect. J. Investig. Dermatol. Symp. Proc. 6(2), 143-147 (2001).
82. Hartmann K, Henz BM. CM - clinical heterogeneity. Int. Arch. Allergy Immunol. 127(2), 143-146 (2002).
83. Brockow K, Scott LM, Worobec AS et al. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: Correlation with clinical patterns of disease. Arch. Dermatol. 138(6), 785-790 (2002).
84. Metcalfe DD. Classification and diagnosis of mastocytosis: Current status. J. Invest. Dermatol. 96(Suppl. 3), 2S-4S; discussion 4S, 60S (1991).
85. Lennert K, Parwaresch MR. MCs and MC neoplasia: A review. Histopathology 3(5), 349-365 (1979).
86. Parwaresch MR, Horny HP, Lennert K. Tissue MCs in health and disease. Pathol. Res. Pract. 179(4-5), 439-461 (1985).
87. Barete S, Assous N, De Gennes C et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann. Rheum. Dis. 69(10), 1838-1841 (2010).
88. Brumsen C, Papapoulos SE, Lentjes EG, Kluin PM, Hamdy NA. A potential role for the MC in the pathogenesis of idiopathic osteoporosis in men. Bone 31(5), 556-561 (2002).
89. Akin C, Scott LM, Metcalfe DD. Slowly progressive systemic mastocytosis with high mast-cell burden and no evidence of a non-mast-cell hematologic disorder: An example of a smoldering case? Leuk. Res. 25(7), 635-638 (2001).
90. Hauswirth AW, Sperr WR, Ghannadan M et al. A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leuk. Res. 26(6), 601-606 (2002).
91. Georgin-Lavialle S, Lhermitte L, Baude C et al. Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a MC precursor. Blood 118(19), 5246-5249 (2011).
92. Pardanani A. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. Am. J. Hematol. 86(4), 362-371 (2011).
93. Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-MC lineage disorders occurring in patients with systemic mastocytosis. Int. Arch. Allergy Immunol. 127(2), 140-142 (2002).
94. Pardanani A, Lim KH, Lasho TL et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 114(18), 3769-3772 (2009).
95. Sperr WR, Walchshofer S, Horny HP et al. Systemic mastocytosis associated with acute myeloid leukaemia: Report of two cases and detection of the c-kit mutation Asp-816 to Val. Br. J. Haematol. 103(3), 740-749 (1998).
96. McClintock-Treep SA, Horny HP, Sotlar K, Foucar MK, Reichard KK. KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: First case report with molecular evidence for same progenitor cell derivation. J. Clin. Pathol. 62(12), 1147-1149 (2009).
97. Fritsche-Polanz R, Fritz M, Huber A et al. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol. Oncol. 4(4), 335-346 (2010).
98. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L et al. Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J. Allergy Clin. Immunol. 124(3), 514-521 (2009).
99. Böhm A, Födinger M, Wimazal F et al. Eosinophilia in systemic mastocytosis: Clinical and molecular correlates and prognostic significance. J. Allergy Clin. Immunol. 120(1), 192-199 (2007).
100. Pardanani A, Ketterling RP, Brockman SR et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102(9), 3093-3096 (2003).
101. Pardanani A, Brockman SR, Paternoster SF et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104(10), 3038-3045 (2004).
102. Florian S, Esterbauer H, Binder T et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): Detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk. Res. 30(9), 1201-1205 (2006).
103. Boldt DH, Kopecky KJ, Head D, Gehly G, Radich JP, Appelbaum FR. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. Leukemia 8(12), 2118-2126 (1994).
104. Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, D'Orazio N. Antileukotriene drugs: Clinical application, effectiveness and safety. Curr. Med. Chem. 14(18), 1966-1977 (2007).
105. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: Current concepts in diagnosis and treatment. Ann. Hematol. 81(12), 677-690 (2002).
106. Laroche M, Livideanu C, Paul C, Cantagrel A. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am. J. Med. 124(8), 776-778 (2011).
107. Laroche M, Bret J, Brouchet A, Mazières B. Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin. Rheumatol. 26(2), 242-243 (2007).
108. Lim AY, Ostor AJ, Love S, Crisp AJ. Systemic mastocytosis: A rare cause of osteoporosis and its response to bisphosphonate treatment. Ann. Rheum. Dis. 64(6), 965-966 (2005).
109. Florian S, Krauth MT, Simonitsch-Klupp I et al. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int. Arch. Allergy Immunol. 136(3), 273-280 (2005).
110. Zanotti R, Bonadonna P, Bonifacio M et al. Isolated bone marrow mastocytosis: An underestimated subvariant of indolent systemic mastocytosis. Haematologica 96(3), 482-484 (2011).
111. Schleyer V, Meyer S, Landthaler M, Szeimies RM. ["Smoldering systemic mastocytosis. "Successful therapy with cladribine]. Hautarzt. 55(7), 658-662 (2004).
112. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br. J. Dermatol. 138(3), 489-495 (1998).
113. Kluin-Nelemans HC, Jansen JH, Breukelman H et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N. Engl. J. Med. 326(9), 619-623 (1992).
114. Gotlib JR, DeAngelo DJ, George TI et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: Report of a fully accrued Phase II trial. Blood 116(21), 144a (2010).
115. Gotlib J. KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol. Allergy Clin. North Am. 26(3), 575-592 (2006).
116. Metcalfe DD. The liver, spleen, and lymph nodes in mastocytosis. J. Invest. Dermatol. 96(Suppl. 3), 45S-46S; discussion 46S, 60S (1991).
117. Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract. Res. Clin. Haematol. 19(3), 595-615 (2006).
118. Nakamura R, Chakrabarti S, Akin C et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant. 37(4), 353-358 (2006).
119. Spyridonidis A, Thomas AK, Bertz H et al. Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant. 34(6), 515-519 (2004).
120. Krauth MT, Böhm A, Agis H et al. Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human MCs and blood basophils. Exp. Hematol. 35(1), 108-116 (2007).
121. Valent P, Cerny-Reiterer S, Herrmann H et al. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human MCs. Best Pract. Res. Clin. Haematol. 23(3), 369-378 (2010).
122. Sperr WR, Horny HP, Lechner K, Valent P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk. Lymphoma 37(5-6), 473-486 (2000).
123. Sperr WR, Walchshofer S, Horny HP et al. Systemic mastocytosis associated with acute myeloid leukaemia: Report of two cases and detection of the c-kit mutation Asp-816 to Val. Br. J. Haematol. 103(3), 740-749 (1998).
124. Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and MCs. Clin. Exp. Allergy 39(11), 1711-1720 (2009).
125. Hadzijusufovic E, Peter B, Gleixner KV et al. H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic MCs. Exp. Hematol. 38(10), 896-907 (2010).
126. Soria JC, Massard C, Magné N et al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur. J. Cancer 45(13), 2333-2341 (2009).
127. Grandpeix-Guyodo C, Dubreuil P, Palmérini F et al. Masitinib for the treatment of systemic and CM with handicap. Am. J. Hematol. 85(12), 921-925 (2010).
128. Hahn KA, Legendre AM, Shaw NG et al. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable MC tumors. Am. J. Vet. Res. 71(11), 1354-1361 (2010).